Aaron Kantor, Frank Torti

Apr 10, 2008

Premium

The Immune Tolerance Institute this week said Aaron Kantor joined the company as chief scientific officer.

Prior to ITI, Kantor was executive director of cell and molecular biology for biomarker discovery sciences at Pharmaceutical Product Development, a contract research organization. Before that, he was manager for the rare cell program and cell depletion therapeutic program at AmCell.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Cleanascite Lipid Removal & Clarification Reference Applications

Albumin Removal Reference Applications

Oct

10

Featured Webinar

Personalization of Oncology Pathways: Clinical Quality Initiatives Amid a Complex Molecular Landscape

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Main menu